1. Home
  2. QLGN vs ALCE Comparison

QLGN vs ALCE Comparison

Compare QLGN & ALCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • ALCE
  • Stock Information
  • Founded
  • QLGN 1996
  • ALCE 2019
  • Country
  • QLGN United States
  • ALCE United States
  • Employees
  • QLGN N/A
  • ALCE N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • ALCE Power Generation
  • Sector
  • QLGN Health Care
  • ALCE Utilities
  • Exchange
  • QLGN Nasdaq
  • ALCE Nasdaq
  • Market Cap
  • QLGN 3.2M
  • ALCE 3.7M
  • IPO Year
  • QLGN N/A
  • ALCE N/A
  • Fundamental
  • Price
  • QLGN $4.07
  • ALCE $0.53
  • Analyst Decision
  • QLGN
  • ALCE
  • Analyst Count
  • QLGN 0
  • ALCE 0
  • Target Price
  • QLGN N/A
  • ALCE N/A
  • AVG Volume (30 Days)
  • QLGN 20.7K
  • ALCE 2.8M
  • Earning Date
  • QLGN 11-14-2024
  • ALCE 11-19-2024
  • Dividend Yield
  • QLGN N/A
  • ALCE N/A
  • EPS Growth
  • QLGN N/A
  • ALCE N/A
  • EPS
  • QLGN N/A
  • ALCE N/A
  • Revenue
  • QLGN N/A
  • ALCE N/A
  • Revenue This Year
  • QLGN N/A
  • ALCE N/A
  • Revenue Next Year
  • QLGN N/A
  • ALCE N/A
  • P/E Ratio
  • QLGN N/A
  • ALCE N/A
  • Revenue Growth
  • QLGN N/A
  • ALCE N/A
  • 52 Week Low
  • QLGN $3.34
  • ALCE $0.50
  • 52 Week High
  • QLGN $29.45
  • ALCE $28.75
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 45.00
  • ALCE 29.99
  • Support Level
  • QLGN $3.95
  • ALCE $0.50
  • Resistance Level
  • QLGN $4.21
  • ALCE $0.55
  • Average True Range (ATR)
  • QLGN 0.27
  • ALCE 0.16
  • MACD
  • QLGN 0.00
  • ALCE 0.00
  • Stochastic Oscillator
  • QLGN 22.08
  • ALCE 2.53

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

About ALCE Alternus Clean Energy Inc.

Alternus Clean Energy Inc is an international independent clean energy producer. It develops, installs, owns and operates a diverse portfolio of utility-scale solar photovoltaic power stations (PV parks) in Europe and the USA as a long-term owner. The solar parks benefit from long-term government offtake contracts and/or Power Purchase Agreements (PPAs) with investment grade off-takers, plus energy sales to local power grids. It has approximately 8 operating parks, a total of 44 MWp in operation.

Share on Social Networks: